Safety Incidents OSHA Severe Injury Reports · 2015–2025
2,276,768Injury reports 135,424Establishments Most recent incident 2025-12-31

OSHA Injury Report: Amphastar Pharmaceuticals

Injury · Job transfer or restriction

On , an injury at Amphastar Pharmaceuticals in AMPHASTAR PHARMACEUTICALS / 11570 6th Street / Rancho Cucamonga, AMPHASTAR PHARMACEUTICALS / 11570 6th Street / Rancho Cucamonga, CA 91730 resulted in job transfer or restriction. Employee was command Post in medicinal chemicals, uncompounded, manufacturing.

Watch Amphastar Pharmaceuticals for free Get an email when a new federal OSHA severe-injury report for Amphastar Pharmaceuticals is published. One employer, no account, unsubscribe in one click.
Parent company
Amphastar Pharmaceutical Inc.
Street
AMPHASTAR PHARMACEUTICALS / 11570 6th Street / Rancho Cucamonga
City
AMPHASTAR PHARMACEUTICALS / 11570 6th Street / Rancho Cucamonga
State
CA
ZIP
91730
On-site location
Bldg. A Area 1401
Outcome
Job transfer or restriction (code 3)
Type
Injury (code 1)
Days restricted or transferred
5

After arriving home she stars filling sharp pain on her right wrist.

Right Wirt tendinitis because of repetitive movements

Right Wirt tendinitis.

none

Right Wirt tendinitis

Job description
Command Post
SOC code
9999: Uncoded
NAICS code
325411: Medicinal chemicals, uncompounded, manufacturing
NAICS vintage
2022
Employees at this establishment (2023 average)
652
Hours worked at this establishment (2023 total)
1,096,017
EIN
330702205
Establishment ID
1029552
Employer case #
4
Date of incident
Time of incident
Not known — the employer filed this case without a time of day.
Filing year
2023
Submitted to OSHA
2024-03-01

View Amphastar Pharmaceuticals's full OSHA safety record →

Data from OSHA ITA Form 300/301 electronic submissions, filing year 2023. ITA Case Detail records are establishment-reported submissions, not OSHA inspections, so no per-record IMIS deep link exists.

Look up any company's OSHA accident reports by company, or browse severe injury reports by year, state, and company.